PTC Therapeutics (NASDAQ: PTCT) insider files Form 144 to sell shares

Rhea-AI Filing Summary

PTC Therapeutics insider Matthew Klein has filed a Form 144 indicating an intent to sell 3,016 shares of common stock through Fidelity Brokerage Services LLC on or about 01/07/2026 on the NASDAQ market. The shares, with an aggregate market value of $233,691.14, were acquired on 01/05/2026 via restricted stock vesting from the issuer as compensation.

Over the prior three months, Klein reported additional sales of the issuer’s common stock, including 3,428 shares on 12/02/2025 for gross proceeds of $271,062.93, 8,089 shares on 12/30/2025 for $619,921.55, and 5,149 shares on 01/06/2026 for $396,203.19. By signing the notice, the seller represents that he is not aware of undisclosed material adverse information about PTC Therapeutics.

FAQ

What does the Form 144 filing for PTC Therapeutics (PTCT) disclose?

The filing shows that Matthew Klein intends to sell 3,016 shares of PTC Therapeutics common stock, with an aggregate market value of $233,691.14, through Fidelity Brokerage Services LLC on or about 01/07/2026 on the NASDAQ.

How were the 3,016 PTC Therapeutics (PTCT) shares being sold acquired?

The 3,016 common shares were acquired on 01/05/2026 via restricted stock vesting from the issuer, with the nature of payment listed as compensation.

What recent PTC Therapeutics (PTCT) stock sales has Matthew Klein reported?

Over the past three months, Matthew Klein reported sales of PTC Therapeutics common stock of 3,428 shares on 12/02/2025 for $271,062.93, 8,089 shares on 12/30/2025 for $619,921.55, and 5,149 shares on 01/06/2026 for $396,203.19.

Which broker and exchange are involved in the planned PTCT share sale?

The planned sale of 3,016 common shares is to be executed through Fidelity Brokerage Services LLC, with trading on the NASDAQ exchange.

What representation does the seller make in the PTC Therapeutics Form 144?

By signing the notice, the person for whose account the securities are to be sold represents that they do not know any material adverse information about the issuer’s current or prospective operations that has not been publicly disclosed.

Does the PTC Therapeutics (PTCT) Form 144 mention Rule 10b5-1 trading plans?

The text notes that if the person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1, signing the form and indicating the plan adoption or instruction date serves as a representation as of that date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/07/2026 - 04:38 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001808968
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	PTC THERAPEUTICS, INC.
SEC File Number	001-35969
Address of Issuer	500 WARREN CORPORATE CENTER DRIVE WARREN NEW JERSEY 07059
Phone	9082227000
Name of Person for Whose Account the Securities are To Be Sold	Klein Matthew B.
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	3016	233691.14	80288305	01/07/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	01/05/2026	Restricted Stock Vesting	Issuer			3016	01/05/2026	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Matthew Klein 500 Warren Corporate Center Drive Warren NJ 07059	Common	12/02/2025	3428	271062.93
Matthew Klein 500 Warren Corporate Center Drive Warren NJ 07059	Common	12/30/2025	8089	619921.55
Matthew Klein 500 Warren Corporate Center Drive Warren NJ 07059	Common	01/06/2026	5149	396203.19

144: Remarks and Signature

Remarks	Sale includes an amount necessary to cover a tax obligation resulting from the settlement of a vested equity award distribution.
Date of Notice	01/07/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Jessica Spraker, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Matthew Klein.
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)